Sodium phosphate, monobasic, unspecified form

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Sodium phosphate, monobasic, unspecified form
Accession Number
DB14503  (DBSALT001972)
Type
Small Molecule
Groups
Approved
Description
Not Available
Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Phosphoric acidunknownE4GA8884NN7664-38-2NBIIXXVUZAFLBC-UHFFFAOYSA-N
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Phosphate ionionicNK08V8K8HR14265-44-2NBIIXXVUZAFLBC-UHFFFAOYSA-K
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Care One EnemaSodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalAmerican Sales Company2010-01-182014-06-07Us
Curad Oral Saline LaxativeSodium phosphate, monobasic, unspecified form (7.2 g/15mL) + Sodium phosphate, dibasic, unspecified form (2.9 g/15mL)LiquidOralMedline Industries2012-07-162016-12-31Us
Curad Oral Saline LaxativeSodium phosphate, monobasic, unspecified form (7.2 g/15mL) + Sodium phosphate, dibasic, unspecified form (2.9 g/15mL)LiquidOralMedline Industries2012-07-162016-12-31Us
Curad Saline LaxativeSodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalMedline Industries2012-07-16Not applicableUs
CVS PharmacySodium phosphate, monobasic, unspecified form (9.5 g/59mL) + Sodium phosphate, dibasic, unspecified form (3.5 g/59mL)EnemaRectalCVS Health2014-05-20Not applicableUs
CVS PharmacySodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalCVS PHARMACY2013-03-08Not applicableUs
Discount Drug Mart EnemaSodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalDiscount Drug Mart2013-12-27Not applicableUs
EnemaSodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalHyvee2009-12-282015-04-22Us
EnemaSodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalMedicine Shoppe International2009-11-202015-04-22Us
EnemaSodium phosphate, monobasic, unspecified form (19 g/118mL) + Sodium phosphate, dibasic, unspecified form (7 g/118mL)EnemaRectalHannaford Brothers Company2009-12-102015-04-22Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DarcalmaSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (36.2 mg/1)TabletOralKylemore Pharmaceuticals, LLC2009-12-012009-12-02Us
DarcalmaSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (36.2 mg/1)TabletOralRiver's Edge Pharmaceuticals, LLC2008-12-222011-07-31Us
OroMinSodium phosphate, monobasic, unspecified form (0.056 g/100g) + Calcium chloride dihydrate (0.054 g/100g) + Sodium fluoride (0.01 g/100g)RinseDentalGermiphene Corporation2017-06-16Not applicableUs
Uro-BLUESodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1)TabletOralMethod Pharmaceuticals2014-12-012015-07-06Us
Urogesic BlueSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1)TabletOralEdwards Pharmaceuticals, Inc2010-04-302017-12-30Us
Urogesic BlueSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1)Tablet, coatedOralEDWARDS PHARMACEUTICALS, INC.2010-11-19Not applicableUs
Urolet MbSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1)TabletOralBurel Pharmaceuticals, Llc2015-06-262016-10-23Us
UtaSodium phosphate, monobasic, unspecified form (40.8 mg/170.92mg) + Hyoscyamine sulfate dihydrate (0.12 mg/170.92mg) + Methenamine (120 mg/170.92mg) + Methylene blue trihydrate (10 mg/170.92mg)CapsuleOralSj Pharmaceuticals, Llc2014-09-26Not applicableUs
UtaSodium phosphate, monobasic, unspecified form (40.8 mg/206.92mg) + Hyoscyamine sulfate dihydrate (.12 mg/206.92mg) + Methenamine (120 mg/206.92mg) + Methylene blue trihydrate (10 mg/206.92mg) + Phenyl salicylate (36 mg/206.92mg)CapsuleOralSTEWART-JACKSON PHARMACAL, INC2002-08-012016-03-08Us
Utira-CSodium phosphate, monobasic, unspecified form (40.8 mg/1) + Hyoscyamine sulfate dihydrate (0.12 mg/1) + Methenamine (81.6 mg/1) + Methylene blue trihydrate (10.8 mg/1) + Phenyl salicylate (36.2 mg/1)TabletOralMission Pharmacal Company2011-09-11Not applicableUs
Categories
UNII
3980JIH2SW
CAS number
Not Available

Pharmacology

Indication

Used to treat constipation or to clean the bowel before a colonoscopy Label.

Associated Conditions
Pharmacodynamics

Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.

Mechanism of action

Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium phosphate, monobasic, unspecified form.
AclidiniumThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aclidinium.
AgmatineThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Agmatine.
AlcuroniumThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Alcuronium.
AlfentanilThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Sodium phosphate, monobasic, unspecified form is combined with Alloin.
AlmasilateThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Almasilate.
AloglutamolThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aloglutamol.
AlphacetylmethadolThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Alphacetylmethadol.
AlphaprodineThe therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Alphaprodine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [PubMed:17652123]
  2. Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [PubMed:18645612]
  3. Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [PubMed:19298584]
  4. Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [PubMed:20958267]
  5. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
  6. FDA Guide: Sodium Phosphate Tablet [Link]
  7. ChemIDPlus: Sodium Phosphate [Link]
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
3Unknown StatusTreatmentMalnutrition1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
LiquidRectal
KitIntravenous
SolutionIntravenous
RinseDental
LiquidOral
EnemaRectal
Tablet, coatedOral
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Not Available
Specific Function
Not Available
Gene Name
SLC20A1
Uniprot ID
Q8WUM9
Uniprot Name
Sodium-dependent phosphate transporter 1
Molecular Weight
73699.01 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Virus receptor activity
Specific Function
Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
Gene Name
SLC20A2
Uniprot ID
Q08357
Uniprot Name
Sodium-dependent phosphate transporter 2
Molecular Weight
70391.755 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
Gene Name
SLC34A1
Uniprot ID
Q06495
Uniprot Name
Sodium-dependent phosphate transport protein 2A
Molecular Weight
68936.53 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
Gene Name
SLC34A2
Uniprot ID
O95436
Uniprot Name
Sodium-dependent phosphate transport protein 2B
Molecular Weight
75758.535 Da
References
  1. Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [PubMed:23398154]
Kind
Protein
Organism
Humans
Pharmacological action
No
General Function
Sodium:phosphate symporter activity
Specific Function
May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
Gene Name
SLC34A3
Uniprot ID
Q8N130
Uniprot Name
Sodium-dependent phosphate transport protein 2C
Molecular Weight
63548.94 Da
References
  1. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [PubMed:12360109]

Drug created on July 11, 2018 11:37 / Updated on December 02, 2019 10:13